[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-ii-diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-ii-diabetes-mellitus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,55,102,129,151,174,200,227,252,278,300,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100619107","phase-2-a-study-of-cx11-tablets-in-patients-with-type-2-diabetes-mellitus-100619107",false,"NCT07340320","A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus","Inclusion Criteria\n\nParticipants who meet all of the following criteria will be eligible to participate in this study:\n\n* Adults aged 18 to 75.\n* Diagnosis of type 2 diabetes for at least 6 months.\n* HbA1c between 7.0% and 10.5%.\n* Body mass index (BMI) between 23 and 50 kg\u002Fm².\n* Body weight stable for the past 3 months before joining.\n* Stable dose of metformin (≥1000 mg\u002Fday), with or without SGLT2i, for ≥3 months.\n* Women of childbearing potential (WOCBP): highly effective contraception ≥6 months prior to screening, throughout study, and 90 days post-last dose; negative pregnancy test within 24 hrs of first dose; no intent to donate sperm\u002Fova\n* Agrees to avoid grapefruit\u002Fgrapefruit products\n\nExclusion Criteria\n\nParticipants who meet any of the following criteria will be excluded from this study:\n\n* Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).\n* Type 1 diabetes or a history of diabetic ketoacidosis.\n* Use of any GLP-1 receptor agonist within the past 6 months, or any prior exposure to CX11.\n* Use of insulin to control blood sugar within the past 12 months.\n* More than one episode of severe low blood sugar, with awareness of hypoglycemia symptoms.\n* Cardiovascular or cerebrovascular conditions within the past 6 months:\n\n  * Heart attack, coronary angioplasty, or bypass surgery (diagnostic angiography allowed).\n  * Valvular heart disease or prior heart valve repair surgery.\n  * Unstable angina.\n  * Transient ischemic attack (TIA) or stroke.\n  * Decompensated heart failure (NYHA Class III or IV).\n  * ECG abnormalities indicating significant safety risk, such as supraventricular tachycardia, torsades de pointes, second- or third-degree AV block, myocardial infarction, QTcF \\> 450 ms in males or \\> 470 ms in females, PR interval \\> 220 ms.\n  * Poorly controlled hypertension at screening: systolic ≥ 180 mmHg or diastolic ≥ 100 mmHg.\n* Pancreatic or gallbladder conditions:\n\n  * Acute or chronic pancreatitis.\n  * Symptomatic gallbladder disease (previous cholecystectomy is allowed).\n  * Pancreatic injury or risk factors that increase pancreatitis risk.\n* Thyroid conditions:\n\n  * Poorly controlled abnormal thyroid function on a stable dose before screening.\n  * Clinically significant abnormal thyroid test results at screening.\n  * Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B.\n* Cancer history:\n\n  * Malignancy within the past 5 years, regardless of recurrence or metastasis. Exceptions: localized basal cell skin cancer, low-risk prostate cancer, cervical carcinoma in situ, or high-grade prostatic intraepithelial neoplasia.\n* Gastrointestinal conditions or treatments that may affect drug absorption:\n\n  * Abnormal gastric emptying (e.g., gastric outlet obstruction).\n  * Severe chronic gastrointestinal disease, including active ulcer within 6 months.\n  * Crohn's disease, ulcerative colitis, or other inflammatory bowel diseases.\n  * Prior gastrointestinal surgery (except polypectomy and appendectomy).\n  * Long-term use of drugs that directly affect gastrointestinal motility (e.g., mosapride, cisapride).\n* Liver disease:\n\n  * Active liver disease other than nonalcoholic fatty liver.\n  * Chronic active hepatitis B or C.\n  * Primary biliary cirrhosis.\n* Eye disease:\n\n  * Uncontrolled or potentially unstable diabetic retinopathy or maculopathy.\n* Abnormal lab results at screening:\n\n  * eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m² (CKD-EPI).\n  * ALT or AST \\> 2.5 × upper limit of normal (ULN).\n  * Total bilirubin \\> 1.5 × ULN (except known Gilbert's syndrome).\n  * Serum amylase or lipase \\> 1.5 × ULN.\n  * Fasting triglycerides \\> 5.7 mmol\u002FL.\n  * TSH \\> 1.5 × ULN or \\\u003C 1.0 × LLN.\n  * Calcitonin ≥ 20 ng\u002FL.\n  * Hemoglobin \\\u003C 110 g\u002FL (male) or \\\u003C 100 g\u002FL (female).","ALL","18 Years","75 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days.\n\nThe study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug.\n\nAfter screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.",[27],"Type II Diabetes Mellitus",[29,30,31,32,33,34,35,36,37,38,39,40,41],"Type 2 Diabetes Mellitus","HbA1C","Percentage change in HbA1C","Change in Fasting Plasma Glucose","Change in body weight","Body weight loss","Hypoglycemics episodes","Hypoglycemia","Continuous Glucose Monitoring","Blood glucose","Health Survey Short Form-36","Diabetes treatment satisfaction questionnaire","Columbia-suicide severity rating scale","RECRUITING","2026-05-26",{"date":45,"type":46},"2026-05-28","ACTUAL",{"date":48,"type":46},"2026-02-06",{"date":50,"type":21},"2027-01-07",{"name":52,"class":53},"Corxel Pharmaceuticals","INDUSTRY",45,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":69,"conditions":70,"keywords":78,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100605783","the-groceries-aimed-at-increasing-nutrition-study-100605783","NCT07167004","The GRoceries Aimed at Increasing Nutrition Study","Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives","GRAINS","Inclusion Criteria:\n\n* Age 45 - 70 years.\n* Able to provide consent.\n* Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania.\n* Consume \\\u003C5 servings of whole grains per week.\n* Use online grocery shopping at least once per month.\n* Have access to a credit or debit card to pay for groceries purchased.\n* Have reliable internet access.\n* Speak English.\n* Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11).\n\nExclusion Criteria:\n\n* Does not meet all the inclusion criteria.\n* Not able to speak English.\n* Not able to provide consent.","45 Years","70 Years",{"count":66,"type":21},216,[68],"NA","Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.",[71,27,72,73,74,75,76,29,77],"Type 2 Diabetes","Type II Diabetes","Pre-diabetes","Pre-diabetic","Pre-diabetic State","Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes (T2DM)",[79,80,81,82,83,84,85,86,87,88,89,90],"chronic disease","diabetes","diabetes mellitus","type II diabetes","type 2 diabetes","pre-diabetes","prediabetes","whole grains","behavioral economics","marketing nudges","financial incentives","food is medicine","2026-05-15",{"date":93,"type":46},"2026-05-19",{"date":95,"type":46},"2025-10-14",{"date":97,"type":21},"2027-02-16",{"name":99,"class":100},"University of Pennsylvania","OTHER",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":101},"100631075","phase-1-cfmsc-therapy-for-diabetes-100631075","NCT07495956","cfMSC Therapy for Diabetes","Clonal Fetal Mesenchymal Stem Cell (cfMSC) Therapy for Type II Diabetes Mellitus","Inclusion Criteria:\n\n1. Ability to understand the study protocol and voluntarily sign the written informed consent form;\n2. A clear diagnosis of type II diabetes mellitus for more than 3 years, with poor blood glucose control under conventional treatment (HbA1c ≥ 7.5% for 3 consecutive months);\n3. Age 18-75 years old, with a body mass index (BMI) of 18.5-35 kg\u002Fm²;\n4. Fasting C-peptide level 0.3-1.5 ng\u002FmL, indicating residual islet function;\n5. Karnofsky performance score (KPS) ≥ 70, with good daily living ability;\n6. Life expectancy \\> 5 years;\n7. Normal liver and kidney functions (bilirubin \\\u003C 1.5×ULN, ALT\u002FAST \\\u003C 2.5×ULN, creatinine \\\u003C 1.5×ULN); normal blood routine (absolute neutrophil count ≥ 1.8×10\\^9\u002FL, platelets ≥ 100×10\\^9\u002FL);\n8. No serious heart, brain, lung and other important organ diseases, and stable vital signs;\n9. Women of childbearing age have a negative pregnancy test within 7 days before enrollment, and all subjects of childbearing age agree to take effective contraceptive measures during the study and within 1 year after the end of the study; Willing to cooperate with the whole course of follow-up and complete all examination and observation indicators.\n\nExclusion Criteria:\n\n1. Type 1 diabetes mellitus or other special types of diabetes;\n2. Severe diabetes-related complications, such as end-stage renal disease, severe proliferative retinopathy, diabetic foot with ulcer and infection, etc.;\n3. A history of malignant tumors within 5 years, or current suspicious malignant tumor lesions;\n4. HIV, hepatitis B, hepatitis C and other infectious diseases with positive pathogen indicators;\n5. Active autoimmune diseases, or long-term use of glucocorticoids and immunosuppressants (except for small dose hormone replacement therapy);\n6. A history of severe allergic reactions, or allergy to the components of the study cell preparation;\n7. Pregnant or lactating women;\n8. Actively participating in other clinical research projects at the same time;\n9. Mental diseases or poor compliance that cannot cooperate with the study; Other conditions that the investigator deems unsuitable for participating in the study.",{"count":110,"type":21},30,[112,24],"PHASE1","The purpose of this study is to assess the feasibility, safety and clinical efficacy of the novel clonal fetal mesenchymal stem cell (cfMSC) therapy in patients with type II diabetes mellitus.",[27],[116,117,118,119],"Clonal fetal MSCs (cfMSCs)","Islet function reconstruction","Insulin resistance","Type II diabetes mellitus","2026-03-22",{"date":122,"type":46},"2026-03-27",{"date":124,"type":46},"2026-03-16",{"date":126,"type":21},"2030-04-30",{"name":128,"class":100},"Shenzhen Geno-Immune Medical Institute",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100614680","phase-2-efficacy-and-safety-of-gl0034-in-overweight-or-obese-adults-with-type-ii-diabetes-mellitus-100614680","NCT07282743","Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus","A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of GL0034 Among Type II Diabetes Mellitus Subjects Who Are Obese or Overweight With Weight-related Comorbidities","Inclusion Criteria:\n\n1. Participant is willing and able to sign a written ICF or e-ICF.\n2. Men or women ≥18 years of age at the time of signing ICF or e-ICF.\n3. Participant was diagnosed with type II diabetes mellitus at least 180 days prior to the day of screening.\n4. Participant has a HbA1c level of 7.0 - 10.5%, both inclusive, at the time of screening.\n5. Participant has a stable BMI ≥27 kg\u002Fm2 for at least 90 days prior to screening.\n6. Participant is able and willing to undergo fasting blood draw (i.e. at least 8 hours after last eating or drinking) as well as 7-point SMBG check for 3 consecutive days prior to designated scheduled visits by using a home glucometer that is provided by the study site.\n7. Participant on stable daily doses of metformin for at least 90 days prior to screening.\n8. Participant who are on metformin and not the following agents for at least 3 months prior to screening: DPP-4 inhibitors, alpha-glucosidase enzyme inhibitors, sulfonylureas, sodium-glucose transport 2 inhibitors, amylin analogues, thiazolidinediones, any insulin product, herbals, or ayurvedic agents. Participants are encouraged to follow the standard of care in their study regions, including appropriate diet and lifestyle modifications, rather than make abrupt change in the diabetic management prior to screening without consulting their physicians.\n9. If participant is a woman of childbearing potential (WOCP)\\*, she must agree to use a highly effective method of contraception during the study in conjunction with a barrier method of contraception, and continue the same contraception method at least one months after the last dose of study drug. Highly effective methods of contraception include one of the following: intrauterine device, injectable hormonal contraceptive, contraceptive patch or implant, partner's vasectomy, bilateral tubal occlusion, and sexual abstinence.\n\n   \\*WOCP includes women who are not surgically sterilized \\[using hysterectomy\u002Fbilateral salpingectomy\u002Fbilateral oophorectomy\\] or post-menopausal \\[defined as 12 consecutive months of amenorrhea without an alternative medical cause\\].\n10. Male participants with female partners of child-bearing potential must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy) during the study. In addition, male participants agree to use the same method of contraception for an additional 30 days after the last IP dose and refrain from donating sperm during this period. In the event that the female partner of the male participant becomes pregnant during the study period + 30 days after the last IP dose, an ICF will be provided to the female partner in order to monitor the female partner, pregnancy, and the newborn.\n11. If participant is a WOCP, she must have a negative serum pregnancy test (SPT) at Screening and a negative urine pregnancy at baseline, with results available before IP administration.\n12. Participant is willing and able to comply with the study protocol, visit schedule, and other study-related instructions and procedures.\n13. Participant is willing and able to independently record the response on various scales and make entries using the e-Patient reported outcomes (ePRO) device.\n\nExclusion Criteria:\n\n1. Participants who have a history of type I diabetes mellitus.\n2. A self-reported change in \\>5% of body weight within 90 days before screening irrespective of medical records.\n3. History of pancreatitis (acute or chronic) or \\>3 hypoglycemic episodes (blood glucose level \\\u003C70 mg\u002FdL or 3.9 mmol\u002FL) within 90 days prior to screening.\n4. Diagnosis of chronic kidney disease with estimated glomerular filtration rate \\\u003C60.\n5. Poorly controlled hypertension with systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg.\n6. Poorly controlled hypothyroidism defined as thyroid-stimulating hormone \\>6 mIU\u002FL or \\\u003C0.4 mIU\u002FL.\n7. Diabetes mellitus and\u002For obesity that is induced by endocrine disorders (e.g. Cushing Syndrome) or medication use (e.g. corticosteroids) as judged by the Investigator.\n8. Previous surgical treatment for obesity (liposuction and\u002For abdominoplasty performed \\>1 year before screening is allowed). Previous or planned (during the trial period) obesity treatment with surgery or a weight loss device. However, previous interventions that, due to reversal or removal, does not have any influence on the participant's weight, in the opinion of the Investigator, are allowed.\n9. History of major depressive disorder within 2 years before randomization.\n10. History of other severe psychiatric illnesses (i.e. schizophrenia, bipolar disorder).\n11. Any lifetime history of a suicidal attempt.\n12. Participants with any medical condition \\[i.e. gastroparesis, uncontrolled gastroesophageal reflux disease, or diarrhea with or without a diagnosis of a diagnosis of irritable bowel syndrome\\] that, in the opinion of the Investigator, can confound study efficacy assessments or safety concerns.\n13. Participant had a myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to IP administration.\n14. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, sudden cardiac death, unexplained death, long QT syndrome, or death from a primary dysrhythmia potentially associated with QT prolongation in any family member.\n15. Surgery scheduled for the trial duration period, except for very minor surgical procedures in the opinion of the Investigator.\n16. Participants with active malignancy.\n\n    Note: participants with past history of malignancy may be included if:\n    * Participant has history of basal cell or in-situ squamous cell carcinoma of skin that has been adequately treated and resolved, per Investigator's judgement.\n    * Participant has history of other malignancy that have been adequately treated with no evidence of recurrence\u002Frelapse within the last 5 years, per Investigator's judgement.\n17. Presence of diabetic retinopathy \\[both nonproliferative diabetic retinopathy and proliferative diabetic retinopathy\\]) or maculopathy in either eye that was verified by a fundoscopic examination within 90 days prior to screening or during the study.\n18. Known moderate to severe coronary, carotid, or peripheral vascular disease that has planned or will likely need revascularization during the study.\n19. Participants with any other condition, which in the opinion of the Investigator, precludes participation in the study (either poses an unacceptable risk to the participant or interferes with assessment\u002Finterpretation of study outcomes).\n20. Known hypersensitivity to the study IP or its excipients.\n21. History of alcohol or drug abuse in the previous two years (Alcohol abuse in this study is defined as \\>14 standard drinks per week in men or \\>7 standard drinks per week in women ± a history of alcohol withdrawal symptoms ± institutionalized\u002Fhospitalized due to alcohol use ± binge drinking with \\>5 standard drinks on a single occasion in men or \\>4 standard drinks on a single occasion in women).\n22. Participants are taking, or will start, medications with narrow therapeutic index such as digoxin, warfarin, etc, or those that will prolong QTc interval.\n23. Participants received any medications for the treatment of type II diabetes mellitus other than those stated in the inclusion criteria within 90 days before screening. Short-term insulin treatment for a maximum of 7 days prior to screening is allowed. Prior insulin treatment for gestational diabetes is also allowed.\n24. Participants who have used medications in the family of GLP-1 agonists in the past.\n25. Treatment with any herbal diet supplements, over-the-counter diet medications as an attempt to lose weight within 90 days before screening.\n26. Treatment with orlistat, lorcaserin, zonisamide, topiramate, phentermine, buproprion, or naltrexone that could promote weight loss within 90 days before screening.\n27. Participation in any organized or online weight-reduction program (i.e. Weight Watchers) within 90 days before screening.\n28. Screening calcitonin ≥50 ng\u002FL (pg\u002FmL).\n29. Participants having clinically significant abnormal values on Screening laboratory tests or other evidence of uncontrolled disease involving any system-organ (e.g., cardiovascular, pulmonary, renal, hepatic, neurological, endocrine, gastrointestinal, psychiatric etc.) that, in the opinion of the Investigator, would put the participant at risk by participating in the study.\n30. Participants with positive urine drug screen \\[amphetamine, barbiturate, benzodiazepine, cocaine, opiates\\] with substances that are not part of participant's routine medical care. Tetrahydrocannabinols is acceptable for as long as its use is legally allowed by participant 's home state or country.\n31. Participants have clinically significant ECG abnormality , including QTcF \\>450 msec for males and \\>470 msec for females, or at high risk for arrhythmia such as judged by the Investigator conditions listed in Criteria #13 above, brady-arrhythmias, tachy-arrhythmias, ventricular arrhythmias, torsade de pointes, high-degree atrioventricular block, or New York Heart Association Class III and IV congestive heart failure.\n32. Pregnant or lactating females.",{"count":137,"type":21},285,[24],"This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or placebo arm (once a week, subcutaneous injection) following initial dose-up titration that takes up to approximately 20 weeks. The primary end point is change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants.",[27],"2026-03-17",{"date":143,"type":46},"2026-03-18",{"date":145,"type":46},"2026-01-20",{"date":147,"type":21},"2027-08",{"name":149,"class":53},"Sun Pharmaceutical Industries Limited",21,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},"100622586","phase-1-study-to-evaluate-if-exposure-to-drug-is-impacted-in-participants-with-renal-insufficiency-100622586","NCT07385547","Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency","A Phase 1 Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of GL0034","Inclusion Criteria:\n\n1. Participant is willing and able to sign a written or electronic informed consent.\n2. Participant is an adult male or female, aged between 18 and 80 years of age, inclusive, at the time of screening.\n3. Participant has eGFR as defined by CKD-EPI equation and converted to the unit of mL\u002Fmin according to the following ranges:\n\n   * eGFR ≥ 90 mL\u002Fmin;\n   * eGFR ≥ 30-59 mL\u002Fmin;\n   * eGFR \\\u003C 30 mL\u002Fmin, not on dialysis;\n   * eGFR \\\u003C 30 mL\u002Fmin, on intermittent hemodialysis.\n4. Participant has a body mass index ≥ 18 kg\u002Fm2 and ≤ 42 kg\u002Fm2 at the Screening visit.\n5. Contraception requirements:\n\n   Female participants must:\n\n   If of reproductive age and sexually active, be willing and able to use a medically highly effective form of birth control 4 weeks prior to and for 30 days following the dose of trial medication. Examples of medically highly effective forms of birth control are:\n   1. Confirmed infertility due to surgical procedure or post-menopausal (cessation of menses for at least 12 months prior to Screening).\n   2. Confirmed infertility of sexual partner or partner of the same sex.\n   3. Hormonal contraceptive (oral, combined, patch, vaginal ring, injectable, implant) in females.\n   4. Double-barrier method (any combination of physical and chemical methods).\n   5. Intrauterine device with a failure rate less than 1% per year.\n\n      Male participants must:\n   6. Agree to use, with their partners, one of the highly effective contraceptive methods, from Baseline until at least 30 days following last dose of trial drug.\n   7. Refrain from donating sperm during the trial and for at least 30 days after the end of the trial.\n6. Participant is willing and able to comply with the study protocol, visit schedule, and other study-related instructions and procedures.\n\n   Participants with Renal Impairment\n7. The participant must have no clinically significant change in disease status within the last 30 days before screening, as documented by the participant's recent medical history.\n8. The participant must have a condition consistent with renal impairment, for at least 3 months, and associated symptoms, but otherwise be determined to be in good health in the opinion of the Investigator.\n9. The participant must have blood pressure (after the participant is supine for at least 5 minutes) between 90 and 160 mmHg systolic, inclusive, and not higher than 110 mmHg diastolic. If blood pressure is out of range, up to 2 repeated assessments are permitted at Screening and check-in. Pulse should not be higher than 110 beats per minute (bpm).\n10. Concomitant medications to treat underlying disease states or medical conditions related to renal impairment are allowed, however must be on a stable dose of medication and\u002For treatment regimen for at least 4 weeks before dosing as well as during the study.\n\nExclusion Criteria:\n\n1. Participant has a screening calcitonin ≥ 50 ng\u002FL (pg\u002FmL).\n2. Participant is on continuous renal replacement therapy or peritoneal dialysis.\n3. Participant has a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome (MENS) type 2.\n4. Participant has a history of pancreatitis (acute or chronic).\n5. Participant is taking medications with a narrow therapeutic index such as digoxin, warfarin, etc.\n6. Participant has a history of major depressive disorder within 2 years before randomization.\n7. Participant has any lifetime history of a suicidal attempt.\n8. Participant has any medical condition that, in the opinion of the Investigator, can confound study assessments or safety concerns.\n9. Participant has a known hypersensitivity to the study medications or excipients.\n10. Participant has clinically significant abnormal values on Screening laboratory tests or other evidence of uncontrolled disease involving any system-organ (e.g., cardiovascular, pulmonary, hepatic, neurological, endocrine, GI, psychiatric, etc.) that, in the opinion of the Investigator, would put the participant at risk by participating in the study.\n11. Participant has a positive urine drug screen (amphetamine, barbiturate, benzodiazepine, cocaine, opiates, tetrahydrocannabinols). A positive test is allowed in case the participant receives a prescription drug responsible for the positive test. Waived for ESRD participants with no urine output.\n12. Participant had a myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to investigational product administration.\n13. Participant has a clinically significant ECG abnormality as judged by the Investigator.\n14. Participant has an active malignancy.\n\n    Note: participants with past history of malignancy may be included if:\n    * Participant has a history of basal cell or in-situ squamous cell carcinoma of skin that has been adequately treated and resolved, per Investigator's judgement.\n    * Participant has a history of other malignancy that have been adequately treated with no evidence of recurrence\u002Frelapse within the last 5 years, per Investigator's judgement.\n15. Participant has a history of alcohol or drug abuse in the previous two years.\n16. Participant has any of the following laboratory abnormalities at Screening:\n\n    * Aspartate aminotransferase or alanine aminotransferase ≥ 3 times the upper limit of normal.\n    * Serum total bilirubin ≥ 1.5 mg\u002FdL (Note: participants with elevated total bilirubin which, as per Investigator's clinical judgement, is thought to be due to Gilbert's syndrome may be included).\n    * White blood cell count \\\u003C 3.0 x 103\u002FμL.\n    * International normalized ratio (INR) ≥ 1.3.\n    * Hemoglobin \\\u003C 11.0 g\u002FdL in participants with normal renal function or hemoglobin \\\u003C 9.0 g\u002FdL in participants with moderate or severe renal impairment.\n17. Participant has a known history of coagulopathy such that SC injection will result in excessive bleeding at the injection sites.\n18. Participant has a positive serology for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. A participant who is hepatitis C virus (HCV) antibody negative can be included in the study. A participant with positive HCV antibodies shall be tested for HCV-ribonucleic acid (RNA). If tested negative, the participant can be included in the study.\n19. Participant participated in another interventional study or received another investigational drug\u002Fdevice\u002Fbiologic within 30 days or 5 half-lives (whichever is longer) of study intervention.\n20. Participant has been placed in an institution on official or judicial orders.\n21. Participant is related to or dependent on the Investigator, Sponsor, or study site such that a conflict of interest may arise.\n22. Participant has any condition, which, in the opinion of the Investigator, precludes participation in the study (either poses an unacceptable risk to the participant or interferes with assessment\u002Finterpretation of study outcomes).",true,"80 Years",{"count":161,"type":21},40,[112],"This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal impairment, severe renal impairment without dialysis, and severe renal impairment with dialysis. Each participant will receive a single subcutaneous dose of GL0034. Blood samples will be collected for PK analysis. Secondary objectives include assessing safety and tolerability. The study will help determine whether renal impairment affects GL0034 exposure and inform dosing recommendations for patients with compromised renal function.",[27],"2026-03-11",{"date":167,"type":46},"2026-03-13",{"date":169,"type":46},"2026-02-25",{"date":171,"type":21},"2026-09-27",{"name":149,"class":53},3,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":158,"sex":16,"minAge":17,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":199},"100451881","phase-4-real-world-safety--efficacy-experience-of-empagliflozin-with-or-without-metformin-in-t2dm-patients---ease-study-100451881","NCT05164263","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus","EASE","Inclusion Criteria:\n\nPatient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL\u002Fmin\u002F1.73m2.\n\nExclusion Criteria:\n\nType 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and\u002For hepatic dysfunctions, where RFT and Urine R\u002FE is abnormal, Diabetic Ketoacidosis and\u002For hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.","65 Years",{"count":184,"type":21},2000,[186],"PHASE4","Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.\n\nStudy design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.\n\nSample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).\n\nFollow up visits: After recruitment, patient is supposed to have three visits for follow-ups.\n\nVisit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.\n\nLABORATORY TESTING:\n\nReputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R\u002FE. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.\n\nWhere in Urine Routine Examination (Urine R\u002FE), we consider as follows:\n\n* Visual Examination:\n\n  * Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.\n  * Urine clarity: Clear, slightly Cloudy, cloudy or turbidity\n* Chemical Examination:\n\n  * Specific gravity\n  * pH\n  * Bilirubin\n  * Urobilinogen\n  * Protein\n  * Ketone\n  * Leukocyte Esterase\n* Microscopic Examination:\n\n  * Red Blood Cells:\n  * Epithelial Cells:\n  * Amorphous:\n  * Pus Cells\n  * Bacteria\n  * Yeast\n  * Casts\n  * Crystals\n\nWhere in Renal Function Test (RFT), we consider as follows:\n\n* Blood Urea Nitrogen (BUN): mg\u002FdL\n* Serum Creatinine: mg\u002FdL\n* Estimated Glomerular Filtration Rate (eGFR): mL\u002Fmin\u002F1.73 m2",[27,189,190],"Efficacy, Self","Safety Issues",{"date":192,"type":46},"2026-01-22",{"date":194,"type":46},"2021-04-01",{"date":196,"type":21},"2027-08-31",{"name":198,"class":53},"Getz Pharma",6,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":158,"sex":16,"minAge":208,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":101},"100619905","engagement-of-community-through-participatory-learning-and-action-for-control-and-prevention-of-type-ii-diabetes-and-its-risk-factors-100619905","NCT07350694","Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors","Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D-Afg]: Feasibility Trial in Rural Kabul-Afghanistan","EMPOWER-D-Afg","Inclusion Criteria:\n\n* For intervention phase: Individuals aged 20 years and above. For baseline and endline assessments (before and after the intervention): Individuals aged 30 years and above.\n* Participants residing in the randomized clusters of Kabul, Afghanistan Individuals willing to participate in the study and provide consent.\n* All individuals with normoglycemia, intermediate hyperglycaemia, and diabetes are encouraged to participate.\n* Participants who can attend the scheduled meetings and interventions as per the study protocol.\n\nExclusion Criteria:\n\n* For Intervention phase: Individuals below the age of 20 years. For baseline and endline assessments (before and after the intervention): individuals below the age of 30 years.\n* Individuals unwilling to provide consent for participation.\n* Participants with reported health conditions that may hinder their active involvement in the study.\n* Individuals with non-compliance with research protocols","20 Years",{"count":210,"type":21},250,[68],"This project aims to adapt, implement, and evaluate PLA based intervention in Rural Kabul, Afghanistan for TIIDM prevention and control.",[214,27],"Diabetes Type 2",[216,217,27,218],"Community-Based Participatory Research","Participatory Learning and Action Research","Intermediate hyperglycemia","2026-01-11",{"date":145,"type":46},{"date":222,"type":46},"2024-12-24",{"date":224,"type":21},"2027-09-30",{"name":226,"class":100},"HealthNet Transcultural Psychosocial Organization",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":158,"sex":16,"minAge":208,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":101},"100559207","engagement-of-community-through-participatory-learning-and-action-for-control-and-prevention-of-type-ii-diabetes-and-its-risk-factors-empower-d-100559207","NCT06561126","Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]","Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]: Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals aged 20 years and above.\n* Participants residing in the rural areas of Peshawar and Swabi, Pakistan.\n* Individuals willing to participate in the study and provide consent.\n* Both individuals with normoglycemia, intermediate hyperglycemia, and diabetes are encouraged to participate.\n* Participants who can attend the scheduled meetings and interventions as per the study protocol.\n\nExclusion Criteria:\n\n* Individuals below the age of 20 years.\n* Individuals unwilling to provide consent for participation.\n* Participants with severe health conditions that may hinder their active involvement in the study.\n* Individuals with a history of non-compliance with medical interventions or research protocols",{"count":235,"type":21},12744,[68],"This project aims to adapt, implement, and evaluate Participatory Learning and Action (PLA) based intervention in rural areas of KPK, Pakistan which includes Peshawar and Swabi for TIIDM prevention and control. The pivotal components of this approach include adapting, implementing, and evaluating the PLA-based intervention for the prevention and control of Type II diabetes. These components will be tailored to meet the specific needs of two different settings in Peshawar and Swabi, Pakistan.\n\nType II Diabetes Mellitus (TIIDM) is considered the fastest-growing health emergency, affecting 537 million adults worldwide. Global projections for the year 2045 suggest that a 12.2% rise in TIIDM is anticipated with an additional 11.4% rise for intermediate hyperglycemia (IHG) \\[1\\]. Around 80% of people with TIIDM reside in low-and middle-income countries (LMICs), exhausting the already burdened healthcare system \\[2\\]. The intervention \"Community groups or mobile phone messaging to prevent and control type 2 diabetes and intermediate hyperglycemia in Bangladesh (DMagic)\" has been tested and found effective in the rural context of Bangladesh \\[1-3\\]. A full trial will be conducted in the rural areas of Peshawar and Swabi, Pakistan.\n\nIt is anticipated that with the use of evidence-based approaches, best practices, and meaningful community participation, PLA is expected to enhance social and behavioural determinants of health and subsequent outcomes. This will further pave the way for the control of other NCDs through a similar focused approach.",[27,239],"Intermediate Hyperglycemia (IHG)",[241,242,27,218],"Community-Based Participatory","Diabetes Mellitus","2025-08-29",{"date":245,"type":46},"2025-09-02",{"date":247,"type":46},"2025-05-01",{"date":249,"type":21},"2026-08-31",{"name":251,"class":100},"Khyber Medical University Peshawar",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":268,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":101},"100599427","combination-of-lactulose-and-polyethylene-glycol-electrolytes-powder-peg-els-for-bowel-preparation-in-type-ii-diabetes-mellitus-patients-100599427","NCT07084350","Combination of Lactulose and Polyethylene Glycol Electrolytes Powder (PEG-ELS) for Bowel Preparation in Type II Diabetes Mellitus Patients","Efficacy and Safety of Oral Lactulose Combined With Polyethylene Glycol Electrolytes Powder (PEG-ELS) for Bowel Preparation in Type II Diabetes Mellitus Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. age 18\\~75 years;\n2. patients undergoing colonoscopy;\n3. diagnosis of type II diabetes mellitus；\n4. sign the informed consent form.\n\nExclusion Criteria:\n\n1. severe heart, lung or liver diseases;\n2. bowel resection;\n3. intestinal obstruction and massive ascites;\n4. women preparing for pregnancy or those who were pregnant and lactating;\n5. mental disorders;\n6. dysphagia;\n7. allergy to any medication used for bowel preparation;\n8. have used prokinetic agents (such as domperidone or mosapride) within 14 days prior to the colonoscopy;\n9. galactose or fructose intolerance, lactase deficiency, galactosemia, or glucose-galactose malabsorption syndrome.",{"count":260,"type":21},254,[68],"Compared to the general population, diabetic patients have a significantly higher rate of inadequate bowel preparation. The European Society of Gastrointestinal Endoscopy (ESGE) guideline recommends polyethylene glycol (PEG) as the preferred bowel-cleansing agent, but there is currently no standardized bowel preparation protocol specifically for diabetic patients. Previous studies have shown that oral lactulose-based regimens or adding lactulose to the standard PEG protocol can improve bowel preparation quality, reduce adverse effects such as abdominal pain, bloating, nausea, and vomiting, and have no impact on blood glucose levels in diabetic patients after consuming 20g or 30g of lactulose. Herein, a multicenter randomized controlled trial(RCT) has been designed to explore the efficacy and safety of lactulose combined with polyethylene glycol electrolyte solution (PEG-ELS) for bowel preparation in patients with type II diabetes mellitus.",[27],[119,265,266,267],"Bowel preparation","Lactulose","Polyethylene glycol","NOT_YET_RECRUITING","2025-08-10",{"date":271,"type":46},"2025-08-14",{"date":273,"type":21},"2025-08-25",{"date":275,"type":21},"2026-07-25",{"name":277,"class":100},"General Hospital of Shenyang Military Region",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":158,"sex":16,"minAge":285,"maxAge":64,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":268,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":101},"100596575","short--and-long-term-effects-of-whole-body-photobiomodulation-in-type-ii-diabetes-patients-a-protocol-for-a-controlled-clinical-trial-100596575","NCT07047248","Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled Clinical Trial","PBM","Inclusion Criteria:\n\n* Adults aged 30 to 70 years.\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) according to the American Diabetes Association (ADA) criteria.\n* HbA1c levels between 6.5% and 10% at screening.\n* Stable diabetes management regimen (medications and lifestyle) for at least three months prior to enrollment\n\nExclusion Criteria:\n\n* Presence of severe diabetic complications (e.g., end-stage renal disease, proliferative diabetic retinopathy).\n* History of photosensitivity or medical conditions exacerbated by light exposure.\n* Use of medications or supplements known to significantly alter glucose metabolism, other than current stable diabetes management.\n* Pregnant or lactating women.","30 Years",{"count":287,"type":21},44,[68],"The development of an integral and global treatment to improve the quality of life in those withType II Diabetes Patients is challenging, thus a whole body Photobiomodulation (PBM) therapy program is proposed as an effective option.",[27],"2025-06-27",{"date":293,"type":46},"2025-07-02",{"date":295,"type":21},"2025-08-30",{"date":297,"type":21},"2026-01-30",{"name":299,"class":100},"University of Malaga",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":158,"sex":16,"minAge":208,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":101},"100559893","feasibility-trial-in-urban-pakistan-for-community-engagement-in-preventing-type-ii-diabetes-and-risk-factors-100559893","NCT06570057","Feasibility Trial in Urban Pakistan for Community Engagement in Preventing Type II Diabetes and Risk Factors","Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]: Feasibility Trial in Urban Pakistan","EMPOWER-D","Inclusion Criteria:\n\n* Individuals aged 20 years and above.\n* Participants residing in the randomized clusters of Karachi, Pakistan\n* Individuals willing to participate in the study and provide consent.\n* Both individuals with normoglycemia, intermediate hyperglycemia, and diabetes are encouraged to participate.\n* Participants who can attend the scheduled meetings and interventions as per the study protocol.\n\nExclusion Criteria:\n\n* Individuals below the age of 20 years.\n* Individuals unwilling to provide consent for participation.\n* Participants with severe health conditions that may hinder their active involvement in the study.\n* Individuals with non-compliance with research protocols",{"count":20,"type":21},[68],"This project aims to adapt, implement, and evaluate PLA based intervention in urban Karachi, Pakistan for TIIDM prevention and control.",[27],[216,217,27,218],"2024-08-22",{"date":315,"type":46},"2024-08-26",{"date":317,"type":46},"2024-06-24",{"date":319,"type":21},"2027-10",{"name":321,"class":100},"Baqai Institute of Diabetology and Endocrinology",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":285,"maxAge":330,"enrollmentInfo":4,"targetDuration":4,"studyType":331,"phases":4,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":339,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":101},"100214213","therapeutic-efficacy-of-abroma-agusta-in-hba1c--in-niddm-100214213","NCT02065674","Therapeutic Efficacy of \"Abroma Agusta\" in HbA1c % in NIDDM","Therapeutic Efficacy of Homoeopathic Mother Tincture of \"Abroma Agusta\" in Changing the Level of Glycated Hb (HbA1c %) in Diabetes Mellitus Type II (NIDDM","ABOMNIDDM","Inclusion Criteria:\n\nInclusion Criteria Age 30 Years above Both Sexes NIDDM FBS - 110-300mg\u002Fdl HbA1c above ≤ 6.5\n\n\\-\n\nExclusion Criteria:\n\n* Patient with major complications like diabetic retinopathy and cardiomyopathy. IDDM HbA1c above 11%","85 Years","EXPANDED_ACCESS","Objective: To ascertain whether homoeopathic medicine ABROMA AUGUSTA has a clinical role in changing the Glycated Hb Level in Diabetes mellitus Type II.\n\nAbstract:\n\nBackground: Type 2 diabetes mellitus (T2DM) is one of the most important epidemic diseases in the world in this century, and accounts for 90% of cases of diabetes globally. Studies have suggested that Abroma Augusta plays a role in acute controlling blood glucose level. The aim of this study was to evaluate the efficacy of \"Abroma Augusta Ѳ\" in chronic control through GlycatedHb (HbA1c %) in Diabetes Mellitus Type 2 (NIDDM) as a pretest post-test study.",[27],[335,336,337,338],"type II Diabetes mellitus","FBS","PPBS","HbA1c%","AVAILABLE","2015-06-05",{"date":342,"type":21},"2015-06-09",{"date":344,"type":4},"2014-02",{"date":346,"type":21},"2014-12",{"name":348,"class":100},"Fr Muller Homoeopathic Medical College"]